Copy Link Print Information

VE-821

55 Cited Publications
Customer Review

Based on 55 publication(s) in Google Scholar

VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM.

For research use only. We do not sell to patients.

  • Purity: 99.67%
  • CAS No.: 1232410-49-9
  • Formula: C18H16N4O3S
  • Molecular Weight:368.41
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • VE-821 Chemical Structure
    VE-821 Chemical Structure
  • Experimental Validation Results for VE-821
  • Experimental Validation Results for VE-821
  • Experimental Validation Results for VE-821
  • Experimental Validation Results for VE-821
  • Experimental Validation Results for VE-821
CAS No.: 1232410-49-9
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) VE-821

More
Customer Validation & Images
Cell Proliferation/Viability AssayWB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB

All ATM/ATR Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • VE-821 Chemical Structure
    VE-821 Chemical Structure
    1/16
  • 1/16

    VE-821 purchased from MedChemExpress. Usage Cited in: Eur J Med Chem. 2017 Feb 15:127:691-702. [Abstract]

    Customer Validation
     Relative cell viability (%) in MDCK CAIX- and CAIX+ cells exposed to ATR inhibitors (VE-821 and VE-822) or the CAIXi conjugated derivatives in combination with radiation during normoxia (21% O2) and anoxia (≤0.02% O2). Normoxic cells are irradiated with 2 Gy and anoxic cells with 4 Gy to induce similar effects on cell viability. Cells were exposed to 500 nM VE-821 and 12, and to 50 nM VE-822 and 13.

  • 1/16

    VE-821 purchased from MedChemExpress. Usage Cited in: Front Oncol. 2017 May 19:7:98. [Abstract]

    Customer Validation
     ATM inhibition by treatment with KU-55933 (10 µM) strongly reduces HR efficiency in JJN3-HR and U266-HR, although cells are still able to perform HR to some extent.

  • 1/16

    VE-821 purchased from MedChemExpress. Usage Cited in: Oncogene. 2016 Sep 8;35(36):4689-97. [Abstract]

    Customer Validation
     Western blotting analysis of lysates from λ820 cells treated with vehicle (0.1% DMSO), 10 μM of the ATR inhibitor VE-821, 1 μM of ATR inhibitor AZ20, 1 μM PI3K/mTOR inhibitor NVP-BEZ235 or indicated concentrations of PI3K/mTOR inhibitor GSK1059615.

  • 1/16

    VE-821 purchased from MedChemExpress. Usage Cited in: DNA Repair. 2016 Apr:40:35-46. [Abstract]

    Customer Validation
     Impact of ATR inhibition on DNA damage response, γ-H2Ax foci formation and cytotoxicity: A representative immunoblot with vinculin used as a loading control(A) shows the impact of ATR inhibition (VE-821) on the early (0.5 h) and late (24 h) DDR to the indicated treatments in H460 cells. pATM fold change shown above the immunoblot (A).

  • 1/16

    VE-821 purchased from MedChemExpress. Usage Cited in: Sahlgrenska Academy. University of Gothenburg. 2016 Mar.

    Customer Validation
     ATRi (VE821) reduces the phosphorylation of CHK1, but not of 4EBP1 or S6, validating our hypothesis.

  • VE-821